Clinical Trial Update: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of Octagam 10% in patients with dermatomyositis has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• Octagam 10% (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Octapharma | Conditions: Dermatomyositis | Phase 3 | Status: COMPLETED | Results posted: 2021-04-21